A UNICANCER phase III trial of hyperthermic intra-peritoneal chemotherapy (HIPEC) for colorectal peritoneal carcinomatosis (PC): PRODIGE 7.

Published on Jun 20, 2018in Journal of Clinical Oncology28.245
· DOI :10.1200/JCO.2018.36.18_suppl.LBA3503
François Quenet25
Estimated H-index: 25
Dominique Elias82
Estimated H-index: 82
+ 14 AuthorsOlivier Glehen46
Estimated H-index: 46
LBA3503Background: Promising results have been obtained during the last decade using cytoreductive surgery (CRS) plus HIPEC for selected patients with colorectal PC who are amenable to complete macroscopic resection. This is the first trial to evaluate the specific role of HIPEC, after CRS, for the treatment of PC of colorectal origin. Methods: Prodige 7 is a randomized phase III, multicenter trial. Patients with histologically proven and isolated PC, peritoneal cancer index (PCI) ≤25 were eligible. Randomization (1:1) was stratified by center, complete macroscopic resection (R0/1 vs R2), and neoadjuvant systemic chemotherapy. Patients were treated with CRS plus HIPEC with oxaliplatin or CRS alone, in association with systemic chemotherapy. The primary endpoint was the overall survival (OS). Secondary endpoints were relapse-free survival (RFS) and toxicity. 264 patients were required to show a gain in median OS from 30 to 48 months (HR = 0.625) with a two-sided α = 0,046 and 80% power. Results: 265 patien...
  • References (0)
  • Citations (66)
📖 Papers frequently viewed together
1,212 Citations
174 Citations
549 Citations
78% of Scinapse members use related papers. After signing in, all features are FREE.
Cited By66
#2M. Kallioinen (Royal College of Obstetricians and Gynaecologists)
Last. R. J. Davies (Cambridge University Hospitals NHS Foundation Trust)H-Index: 3
view all 6 authors...
#1Sang-A Kim (Seoul National University Bundang Hospital)
#2Ji Won Kim (Seoul National University Bundang Hospital)H-Index: 9
Last. Yang Soo Kim (Seoul National University Bundang Hospital)H-Index: 99
view all 14 authors...
PURPOSE: Some metastatic colorectal cancer (mCRC) patients receive conversion surgery (CS), including metastasectomy after palliative chemotherapy. Although targeted agents significantly improved the outcomes, the clinical outcome of CS in the targeted agent era has not yet been thoroughly investigated. METHODS: We analyzed the clinical data of 96 mCRC patients who initially had unresectable liver- and/or lung-limited metastases and underwent first-line cetuximab or bevacizumab plus FOLFIRI betw...
#1C. BakkersH-Index: 1
#2F.N. van ErningH-Index: 6
Last. Alexandra BrandtH-Index: 2
view all 16 authors...
OBJECTIVES: In the Netherlands, limited variability exists in performance of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS-HIPEC) among centers treating colorectal peritoneal metastases (PM), except for the intraperitoneal drug administration. This offers a unique opportunity to investigate any disparities in survival between the two most frequently used HIPEC regimens worldwide: mitomycin C (MMC) and oxaliplatin. METHODS: This was a comparative, population-based cohor...
#1E.C. Hulshof (LUMC: Leiden University Medical Center)
#2R.J. LurvinkH-Index: 1
Last. Maarten J. Deenen (LUMC: Leiden University Medical Center)H-Index: 14
view all 10 authors...
Abstract Introduction Mitomycin C (MMC) is commonly used in patients with colorectal peritoneal metastases (CPM) treated with cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy (CRS + HIPEC). MMC requires metabolic activation prior to exert its cytotoxic effect of which the main activating enzymes are NQO1 and POR. However, not all patients are able to activate MMC for example due to polymorphisms in the genes encoding these enzymes. The aim of this study was to investigate the...
Aim: To evaluate the impact of cytoreductive surgery on the outcomes of patients with metastatic appendiceal carcinoma. Methods: Surveillance, Epidemiology and End Results (SEER) database was accessed and patients with metastatic appendiceal carcinoma diagnosed (2010-2015) were reviewed. Kaplan-Meier survival estimates/log-rank testing were then used to assess overall survival outcomes according to cytoreductive surgery. Multivariable Cox regression analysis was then used to evaluate factors aff...
#1David K. LauH-Index: 4
#2Matthew Burge (UQ: University of Queensland)H-Index: 12
Last. Niall C. Tebbutt (University of Melbourne)H-Index: 48
view all 12 authors...
Introduction: Outcomes in metastatic colorectal cancer are improving, due to the tailoring of therapy enabled by better understanding of clinical behaviour according to molecular subtype.Areas covered: A review of the literature and recent conference presentations was undertaken on the topic of systemic treatment of metastatic colorectal cancer. This review summarises expert discussion of the current evidence for therapies in metastatic colorectal cancer (mCRC) based on molecular subgrouping.Exp...
#1G. C. Van Rhoon (EUR: Erasmus University Rotterdam)H-Index: 25
#2Martine Franckena (EUR: Erasmus University Rotterdam)H-Index: 14
Last. Timo L.M. ten Hagen (EUR: Erasmus University Rotterdam)H-Index: 39
view all 3 authors...
Hyperthermia, i.e. heating the tumor to a temperature of 40-43 degrees C is considered by many a valuable treatment to sensitize tumor cells to radiotherapy and chemotherapy. In recent randomized trials the great potential of adding hyperthermia to chemotherapy was demonstrated for treatment of high risk soft tissue sarcoma: +11.4% 5yrs. overall survival (OS) and for ovarian cancer with peritoneal involvement nearly +12months OS gain. As a result interest in combining chemotherapy with hyperther...
#1Maurits P. Engbersen (UM: Maastricht University)
#2Arend G. J. Aalbers (NKI-AVL: Netherlands Cancer Institute)H-Index: 12
Last. Max J. Lahaye (NKI-AVL: Netherlands Cancer Institute)H-Index: 11
view all 8 authors...
OBJECTIVE: The aim of this study was to determine whether the extent of peritoneal metastases (PMs) on preoperative diffusion-weighted magnetic resonance imaging (DW-MRI) can be used as a biomarker of disease-free and overall survival in patients with colorectal cancer who are considered for cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS/HIPEC). METHODS: For this retrospective cohort study, patients with PMs considered for CRS/HIPEC who underwent DW-MRI for preoperative...
Background The peritoneum is the second most common site for metastasis in patients with colorectal cancer. Various factors have been studied to identify patients at risk of developing peritoneal carcinomatosis (PC), including T4 tumors. The objectives were to assess the incidence of synchronous and metachronous PC, explore potential risk factors for developing PC as the only site of metastasis, and identify which patients might be candidates for prophylactic hyperthermic intraperitoneal chemoth...
#1Wim Ceelen (Ghent University Hospital)H-Index: 32
#2Helena Braet (UGent: Ghent University)
Last. Katrien Remaut (UGent: Ghent University)H-Index: 25
view all 5 authors...
AbstractIntroduction: Peritoneal metastasis (PM) is a common manifestation of ovarian and gastro-intestinal cancer. Compared to parenchymal metastasis, PM is less amenable to systemic chemotherapy,...